# Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo

> **NCT00824356** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 54 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** GSK1004723 (200mg)
- **OTHER:** Placebo
- **DRUG:** GSK1004723 (1000mg)

## Key facts

- **NCT ID:** NCT00824356
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2009-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00824356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00824356, "Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00824356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*